Incyte Corporation (INCY)
Health Care2 articles
Price chart
Incyte Corporation (INCY) overview
Incyte is a biopharmaceutical company focused on oncology. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Incyte Corporation trades on the NasdaqGS under the ticker symbol INCY. As of the most recent market data, the stock was priced around $117.25, up 0.51% on the session, giving Incyte Corporation a market capitalization of roughly $23.42B.
Over the past 52 weeks, INCY has traded between $67.17 and $119.60. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 16.5, a common gauge of how richly the market prices the company's earnings.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch INCY
As one of the larger companies in the Health Care sector, Incyte Corporation is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch INCY for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest INCY news
Incyte Stock (INCY) Surges; Analysts Report Positive Developments
Incyte (INCY) stock saw a significant increase today following positive analyst reports concerning the company's latest clinical trials. The reports indicated a 20% improvement in treatment efficacy compared to previous results. Additionally, the overall trading volume for Incyte rose by 35% compared to the last week. This surge in stock price and volume indicates positive sentiment around the company's prospects and potentially foreshadows future growth in investor interest.
Read More: Incyte Stock (INCY) Surges; Analysts Report Positive Developments
Incyte (INCY) Stock Rating Reaffirmed Following Medicaid Settlement
H.C. Wainwright has reiterated its rating for Incyte (INCY) following a settlement related to Medicaid. The specifics of the settlement are undisclosed, but the firm maintains confidence in the company's prospects. The continuity in the rating suggests stable expectations for the stock moving forward. Market reactions will be monitored as additional details may impact trading volumes and investment sentiment.
Read More: Incyte (INCY) Stock Rating Reaffirmed Following Medicaid SettlementMore Health Care stocks
Frequently asked questions
Is Incyte Corporation in the S&P 500?
Yes. Incyte Corporation (INCY) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is INCY in?
Incyte Corporation is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest INCY news?
This page collects recent Incyte Corporation (INCY) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Incyte Corporation's stock price?
As of the most recent market data, Incyte Corporation (INCY) traded at approximately $117.25. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Incyte Corporation's market cap?
Incyte Corporation has a market capitalization of roughly $23.42B, based on its most recent share price and shares outstanding.
What is INCY's P/E ratio?
INCY trades at a trailing price-to-earnings ratio of about 16.5. The P/E ratio compares a company's share price to its earnings per share.